razoxane has been researched along with cytarabine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (57.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Comelli, A; Massimo, L | 1 |
| Grieder, A; Maurer, R; Stähelin, H | 1 |
| Brugarolas, A; Buesa, JM; Gracia Marco, M; Lacave, AJ; Valle Pereda, M | 1 |
| Shaw, D; Tudhope, GR | 1 |
| Bakowski, MT; Lister, TA; Malpas, JS; McElwain, TJ; Powles, RL; Prentice, HG | 1 |
| Copplestone, JA; Hamblin, TJ; Mufti, GJ; Oscier, DG | 1 |
| Darlow, S; Hamblin, TJ; Mufti, GJ; Nightingale, A; Oscier, DG | 1 |
| Lemez, P; Maresová, J | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
| Antonelli, A; Carpi, A; Cervetti, G; Fallahi, P; Franzoni, F; Galetta, F; Petrini, M; Regoli, F; Santoro, G; Tocchini, L | 1 |
2 trial(s) available for razoxane and cytarabine
| Article | Year |
|---|---|
Limited activity of ICRF-159 in advanced acute leukemia.
Topics: Clinical Trials as Topic; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Piperazines; Razoxane | 1979 |
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bleomycin; Chromans; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Free Radical Scavengers; Glutathione; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Razoxane; Time Factors; Uric Acid; Vincristine | 2010 |
12 other study(ies) available for razoxane and cytarabine
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
[New drugs for the therapy of acute leukemia].
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Guanazole; Humans; Leukemia; Lomustine; Peptichemio; Podophyllotoxin; Razoxane; Zinostatin | 1975 |
Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Line; Colchicine; Cytarabine; DNA, Neoplasm; Etoposide; Mast-Cell Sarcoma; Mechlorethamine; Mercaptopurine; Methotrexate; Mitosis; Neoplasm Proteins; Neoplasms, Experimental; Podophyllotoxin; Razoxane; RNA, Neoplasm; Teniposide; Vincristine; X-Rays | 1977 |
Phase I and II clinical study of anhydro-ara-5-fluorocytosine (AAFC) and ICRF-159 combination in adenocarcinoma of digestive origin.
Topics: Adenocarcinoma; Adult; Aged; Ancitabine; Bone Marrow; Cytarabine; Digestive System Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous | 1978 |
Razoxane in treatment of acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous | 1978 |
Razoxane in treatment of acute myeloid leukaemia.
Topics: Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Razoxane | 1978 |
Monocytic skin infiltration in chronic myelomonocytic leukaemia.
Topics: Aged; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Monocytes; Razoxane; Skin Neoplasms | 1986 |
Serous effusions in monocytic leukaemias.
Topics: Aged; Ascitic Fluid; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Razoxane | 1984 |
Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cytarabine; Daunorubicin; Female; Heart; Humans; Leukemia, Myeloid; Male; Middle Aged; Razoxane; Recurrence | 1996 |
In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
Topics: Acute Disease; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Humans; Inhibitory Concentration 50; Leukemia; Mitoxantrone; Razoxane; Tumor Cells, Cultured | 2001 |
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |